What could oncology care look like by 2030? NCODA Oncology, Advocacy, Health Policy & Equity Fellow and guest host Ariel Hughes, PharmD, is joined by Douglas B. Flora, MD, FACCC, LSSBB, and Kiara Wilson, PharmD, for a forward-looking conversation on the changes already shaping cancer care and what may come next. Dr. Flora is Executive Medical Director of Oncology Services and the Robert and Dell Ann Sathe Endowed Chair in Oncology at the Yung Family Cancer Center at St. Elizabeth Healthcare. A board-certified medical oncologist with more than 20 years of clinical experience, he also serves as Founding Editor-in-Chief of AI in Precision Oncology and is President-Elect of the Association of Community Cancer Centers. His work focuses heavily on the intersection of technology, AI, and the human side of cancer care. Dr. Wilson is an Oncology Medical Science Liaison at Azurity Pharmaceuticals, supporting hematology and oncology across a 16-state Midwest region. Her experience includes multiple myeloma, CAR T-cell therapy, bispecific antibodies, scientific exchange, and oncology launch readiness. She is also the founder of PharmaKi Coaching, where she mentors aspiring pharmacists and supports professional development. Together, they discuss the growing role of AI, CAR T-cell therapy, and bispecific antibodies, earlier and more personalized treatment, remote patient monitoring, and the importance of expanding access to innovative therapies in community oncology. They also explore how technology may help reduce administrative burden, strengthen the patient-provider relationship, and make cancer care more accessible and more human.